Results 61 to 70 of about 206 (148)

Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study. [PDF]

open access: yesEBioMedicine, 2023
Yu HJ   +11 more
europepmc   +1 more source

Editorial. [PDF]

open access: yesAssess Writ, 2020
East M, Slomp D.
europepmc   +1 more source

Natural language processing: state of the art, current trends and challenges. [PDF]

open access: yesMultimed Tools Appl, 2023
Khurana D, Koli A, Khatter K, Singh S.
europepmc   +1 more source

Triage of documents containing protein interactions affected by mutations using an NLP based machine learning approach. [PDF]

open access: yesBMC Genomics, 2020
Qu J   +8 more
europepmc   +1 more source

Medication Rules in Herbal Medicine for Mild Cognitive Impairment: A Network Pharmacology and Data Mining Study. [PDF]

open access: yesEvid Based Complement Alternat Med, 2022
Chang Z   +9 more
europepmc   +1 more source

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab. [PDF]

open access: yesPLoS One, 2021
Demarchi M   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy